#United States #San Diego #Clinical Trials #Viking Therapeutics #VK2735

Viking Therapeutics Successfully Closes Major Offerings

In a significant financial maneuver, Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical firm renowned for developing groundbreaking therapies for metabolic and endocrine disorders, has announced the conclusion of its upsized public offerings. The company raised approximately $575 million from these concurrent offerings, which included 9,035,714 shares of common stock priced at $35.00 each and $258.75 million of convertible senior notes, all due in 2032.

The management of these offerings was collaboratively handled by prominent investment banks including Morgan Stanley, J.P. Morgan, Jefferies, and others, ensuring smooth execution and additional funding opportunities. Notably, the underwriters fully exercised their options to acquire an additional 1,178,571 shares of common stock and $33.75 million in notes, underscoring strong investor confidence in Viking's future prospects.

Strategic Use of Proceeds

Viking has earmarked the proceeds for critical areas such as the clinical development and commercialization of its lead program, VK2735, along with advancing its VK3019 program. The company is focusing on comprehensive research and development efforts, aiming to enhance working capital and cater to general corporate needs.

VK2735 is particularly promising as it functions as a dual agonist activating GLP-1 and GIP receptors, a novel approach in treating obesity. Currently, this program is undergoing Phase 3 studies to validate its efficacy and safety in long-term weight management. Along with VK2735, Viking is also developing VK3019, an amylin receptor agonist, and VK2809, which targets metabolic and liver diseases.

Regulatory Compliance and Transparency

The offerings were conducted under an effective shelf registration statement with the Securities and Exchange Commission (SEC), with Viking ensuring transparency by distributing a prospectus supplement to potential investors. This step underscores Viking's commitment to regulatory compliance and open communication with its stakeholders.

Forward-Looking Outlook

Despite the enthusiasm surrounding these offerings, Viking's management cautions stakeholders as the company faces inherent risks associated with clinical trials and market fluctuations. Forward-looking statements provided in this announcement are indicative of Viking’s beliefs but are subject to change based on various external factors. Investors are encouraged to monitor ongoing developments and regulatory updates that can impact these projections.

As a pioneering company in biopharmaceuticals, Viking Therapeutics is set to make impactful strides in healthcare for conditions that often go untreated. With the substantial funds raised from the recent offerings, it is well-poised to advance its innovative solutions along the path to market success, ultimately aiming to improve the quality of life for patients suffering from metabolic disorders.